Loading the section
Prices delayed by 15 minutes
Next earnings report: 03 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Exelixis, Inc. trades on Nasdaq under the ticker EXEL. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks EXEL has traded between 33.76 $ and 61.14 $. As of 09 October 2026 the price stood 92.26 % of the way from the 52-week low to the high.
Over one year EXEL shares rose 48.93 %; over six months they rose 29.97 %. Volatility over 90 days is 33.09 %. Dividends are not included: this is price change only, as of 09 October 2026.
EXEL trades at a price-to-earnings ratio of 18.0, below the sector median of 24.8. Price to sales is 6.3, above the sector median of 3.9. Price to book is 7.7, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 58.07 | 60.08 | 57.91 | 59.02 | 3M |
| 07 October 2026 | 58.47 | 59.27 | 57.88 | 58.44 | 2M |
| 06 October 2026 | 58.85 | 59.00 | 57.02 | 58.33 | 2M |
| 05 October 2026 | 58.36 | 59.79 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Exelixis is built around a single cancer drug and is widening its use.
The lead drug is used in kidney and liver cancer, often combined with immunotherapy. It supplies the overwhelming share of revenue, and the company is profitable — a rarity for a biotech. That dependence gives a steady stream today and a defined risk date in the future.
Work runs in two directions: widening the approved drug's indications and developing the next generation of molecules meant to replace it before patent protection lapses. Litigation with generic manufacturers is a constant background. Risks: the patent term, trial outcomes and competition in the same indications. The company pays no dividend but buys back stock.
Address:1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502, US
Exelixis, Inc. reported revenue of 2.4B $ and net income of 833M $ over the last four quarters. Net margin is 35.08 %. Revenue changed by +3.33 % year over year. Earnings per share are 3.02 $. Market capitalisation is 15.0B $.
EXEL has a return on equity of 43.05 %, above the sector median of −41.68 %. Return on assets is 32.13 %, above the sector median of −32.11 %. Operating margin is 39.43 %, above the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| 57.82 |
| 58.85 |
| 3M |
| 02 October 2026 | 58.11 | 58.97 | 57.94 | 58.39 | 2M |
| 01 October 2026 | 58.54 | 59.28 | 57.76 | 57.94 | 1M |
| 30 September 2026 | 58.90 | 61.14 | 58.40 | 58.41 | 3M |
| 29 September 2026 | 58.06 | 59.13 | 57.53 | 58.65 | 2M |
| 28 September 2026 | 57.97 | 58.66 | 57.51 | 58.37 | 1M |
| 25 September 2026 | 58.25 | 58.62 | 57.63 | 58.16 | 2M |
| 24 September 2026 | 56.70 | 57.99 | 56.58 | 57.95 | 2M |
| 23 September 2026 | 58.22 | 58.66 | 56.26 | 56.73 | 1M |
| 22 September 2026 | 57.65 | 59.09 | 57.33 | 58.15 | 2M |
| 21 September 2026 | 58.61 | 58.81 | 56.90 | 57.22 | 2M |
| 18 September 2026 | 58.29 | 59.15 | 57.90 | 58.36 | 5M |
| 17 September 2026 | 57.23 | 58.52 | 57.23 | 58.49 | 2M |
| 16 September 2026 | 57.04 | 57.78 | 56.33 | 56.78 | 2M |
| 15 September 2026 | 55.93 | 56.97 | 54.95 | 56.90 | 2M |
| 14 September 2026 | 56.44 | 57.07 | 55.91 | 56.21 | 2M |
| 11 September 2026 | 56.76 | 57.43 | 54.55 | 56.12 | 3M |